RecruitingNot ApplicableNCT06500065

68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas

Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy

Sponsor

Ohio State University Comprehensive Cancer Center

Enrollment

30 participants

Start Date

Sep 30, 2024

Study Type

INTERVENTIONAL

Conditions

Soft Tissue Sarcoma

Summary

This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-DOTATATE. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. 68Ga-DOTATATE digital PET/CT may work better in imaging patients with soft tissue sarcomas.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special PET/CT imaging scan with a radioactive tracer called 68Ga-DOTATATE to see if soft tissue sarcomas (a type of cancer in the body's connective tissues) show up on this scan, which is normally used for other cancer types. **You may be eligible if...** - You are 18 or older with a diagnosis of soft tissue sarcoma at any stage - You are a candidate for systemic therapy (cancer treatment given throughout the body, like chemotherapy) - You have had a standard of care PET/CT scan within 30 days before enrolling at Ohio State University **You may NOT be eligible if...** - You have a known allergy to somatostatin or similar peptides (the class the tracer belongs to) - You have received long-acting somatostatin analog drugs in the past 6 months - You are pregnant or breastfeeding - You are currently incarcerated - You have an active infection or are unable to complete the required scans Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.